Suppr超能文献

淋巴组织细胞增生症样肉芽肿病的发病机制与治疗,一种罕见的 EBV 驱动的疾病。

Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder.

机构信息

Lymphoid Malignancies Branch, Center for Cancer Research and.

Laboratory of Pathology, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD.

出版信息

Blood. 2020 Apr 16;135(16):1344-1352. doi: 10.1182/blood.2019000933.

Abstract

Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus (EBV)-driven B-cell lymphoproliferative disease (LPD). This disease is hypothesized to result from defective immune surveillance of EBV, with most patients showing evidence of immune dysfunction, despite no known primary immunodeficiency. Pathologically, LYG is graded by the number and density of EBV+ atypical B cells, and other characteristic findings include an angioinvasive/angiodestructive reactive T-cell infiltrate and various degrees of necrosis. Clinically, LYG universally involves the lungs with other common extranodal sites, including skin, central nervous system, liver, and kidneys. Nodal and/or bone marrow involvement is extremely rare and, if present, suggests an alternative diagnosis. Treatment selection is based on histologic grade and underlying pathobiology with low-grade disease hypothesized to be immune-dependent and typically polyclonal and high-grade disease to be immune-independent and typically oligoclonal or monoclonal. Methods of augmenting the immune response to EBV in low-grade LYG include treatment with interferon-α2b, whereas high-grade disease requires immunochemotherapy. Given the underlying defective immune surveillance of EBV, patients with high-grade disease may have a recurrence in the form of low-grade disease after immunochemotherapy, and those with low-grade disease may progress to high-grade disease after immune modulation, which can be effectively managed with crossover treatment. In patients with primary refractory disease or in those with multiple relapses, hematopoietic stem cell transplantation may be considered, but its efficacy is not well established. This review discusses the pathogenesis of LYG and highlights distinct histopathologic and clinical features that distinguish this disorder from other EBV+ B-cell LPDs and lymphomas. Treatment options, including immune modulation and combination immunochemotherapy, are discussed.

摘要

淋巴瘤样肉芽肿病(LYG)是一种罕见的 EBV 驱动的 B 细胞淋巴增生性疾病(LPD)。该疾病被认为是由于 EBV 的免疫监视缺陷所致,尽管没有已知的原发性免疫缺陷,但大多数患者均表现出免疫功能障碍的证据。从病理学上看,LYG 根据 EBV+ 异型 B 细胞的数量和密度进行分级,其他特征性发现包括血管侵袭/血管破坏性反应性 T 细胞浸润和不同程度的坏死。从临床上看,LYG 普遍累及肺部,其他常见的结外部位包括皮肤、中枢神经系统、肝脏和肾脏。结内和/或骨髓受累极为罕见,如果存在,则提示其他诊断。治疗选择基于组织学分级和潜在的病理生物学,低级别疾病被认为是免疫依赖性的,通常是多克隆的,而高级别疾病是免疫独立性的,通常是寡克隆或单克隆的。增强低级别 LYG 中 EBV 免疫反应的方法包括使用干扰素-α2b 治疗,而高级别疾病需要免疫化学治疗。鉴于 EBV 潜在的免疫监视缺陷,高级别疾病患者在免疫化学治疗后可能会以低级别疾病的形式复发,而低级别疾病患者在免疫调节后可能会进展为高级别疾病,交叉治疗可有效管理这种情况。对于原发性难治性疾病或多次复发的患者,可能会考虑造血干细胞移植,但疗效尚未得到充分证实。本文讨论了 LYG 的发病机制,并强调了该疾病与其他 EBV+B 细胞 LPD 和淋巴瘤的独特组织病理学和临床特征。讨论了治疗选择,包括免疫调节和联合免疫化学治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d65d/7162687/806e737e2f0e/bloodBLD2019000933Cabsf1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验